Last reviewed · How we verify
NCT06225336: AUR-201
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
Phase 1 trial testing AUR-201 in Microtia in 2 participants. Terminated before completion.
10 September 2025
Quick facts
| Lead sponsor | Auregen Biotherapeutics, SA |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 4 November 2022 |
| Primary completion | 10 September 2025 |
| Estimated completion | 10 September 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- AUR-201
Conditions studied
- Microtia — all drugs for Microtia →
Sponsor
Auregen Biotherapeutics, SA
Who can join
Adults 8 to 29, any sex, with Microtia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06225336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AUR-201
Trials testing the same drug.
- NCT06078566 — Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 · Phase 1, PHASE2 · terminated
- NCT06072040 — Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia · Phase 1, PHASE2 · terminated
Other recruiting trials for Microtia
Currently open trials in the same condition.
- NCT07154667 — Evaluation of the Auryzon™ EAR 2.0 System in Ear Reconstruction · NA · recruiting
- NCT06394687 — The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule · NA · active not recruiting
- NCT05288790 — Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT · Phase 2 · recruiting
- NCT05929976 — InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort · recruiting
Other Auregen Biotherapeutics, SA trials
Trials by the same sponsor.
- NCT06078566 — Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 · Phase 1, PHASE2 · terminated
- NCT06072040 — Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06225336 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Auregen Biotherapeutics, SA
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06225336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing